Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 20978357)

1.

Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S.

J Clin Invest. 2010 Nov;120(11):3843-54. doi: 10.1172/JCI42059. Epub 2010 Oct 18.

2.

Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.

Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, Glynn SA, Hussain SP, Young HA, Ambs S, Wink DA.

Proc Natl Acad Sci U S A. 2014 Apr 29;111(17):6323-8. doi: 10.1073/pnas.1401799111. Epub 2014 Apr 14.

3.
4.

Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.

Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA.

Breast Cancer Res. 2012 Sep 12;14(5):R125. doi: 10.1186/bcr3319.

5.

S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.

Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, Wink DA.

Mol Cancer Res. 2012 Sep;10(9):1203-15. Epub 2012 Aug 9.

7.

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J.

Breast Cancer Res. 2007;9(1):R16.

8.

Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.

Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.

PLoS One. 2009;4(3):e4710. doi: 10.1371/journal.pone.0004710. Epub 2009 Mar 9.

9.

Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation.

Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY, Heinecke JL, Brueggemann E, Hines HB, Khanna C, Glynn SA, Ambs S, Wink DA.

PLoS One. 2012;7(9):e44081. doi: 10.1371/journal.pone.0044081. Epub 2012 Sep 5.

10.

Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells.

Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF, Wang SM.

Int J Cancer. 2007 Nov 1;121(9):1949-57.

PMID:
17621625
11.

Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.

Martin KJ, Patrick DR, Bissell MJ, Fournier MV.

PLoS One. 2008 Aug 20;3(8):e2994. doi: 10.1371/journal.pone.0002994.

12.

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.

PMID:
19795205
13.
14.

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.

Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94. doi: 10.1158/1055-9965.EPI-11-0343. Epub 2011 Jul 22.

15.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.

16.

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

Breast Cancer Res. 2009;11(2):R15. doi: 10.1186/bcr2234. Epub 2009 Mar 9.

17.

Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.

Bergamaschi A, Christensen BL, Katzenellenbogen BS.

Breast Cancer Res. 2011 Jun 29;13(3):R70. doi: 10.1186/bcr2913.

18.

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

J Clin Oncol. 2010 Apr 10;28(11):1813-20. doi: 10.1200/JCO.2009.22.8775. Epub 2010 Mar 15.

19.

Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.

PMID:
20020198
20.

Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.

Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G, Holtrich U, Karn T, Kaufmann M.

Breast Cancer Res Treat. 2008 Nov;112(1):41-52. Epub 2007 Dec 4.

PMID:
18058224
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk